These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 3549009)

  • 41. Experiences on the efficacy and safety of nalidixic acid, oxolinic acid, cinoxacin and norfloxacin in the treatment of urinary tract infections (UTI).
    Sabbour MS; El Bokl MA; Osman LM
    Infection; 1984; 12(6):377-80. PubMed ID: 6240470
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Clinical evaluation of norfloxacin preparation in treatment of bacterial infections of the urinary tract in patients with various kidney diseases].
    Mazanowska O; Boratyńska M; Mróz E; Starek J
    Pol Tyg Lek; 1994 Feb 7-14; 49(6-7):154-7. PubMed ID: 8090671
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Norfloxacine efficacy in acute cystitis in the region with 10% resistance of E. coli to fluoroquinolones: a comparative randomized study].
    Rafal'skiĭ VV; Malev IV; Derevitskiĭ AV; Kozlov SN; Galkin VV
    Urologiia; 2009; (3):18-21. PubMed ID: 19670810
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Clinical evaluation of cinoxacin in infections of the urinary tract in ambulatory patients].
    Aimè G; Governa M
    Minerva Urol Nefrol; 1986; 38(2):147-50. PubMed ID: 3750156
    [No Abstract]   [Full Text] [Related]  

  • 45. A comparative drug study of lower urinary tract infections in elderly patients.
    Lindan R
    Urology; 1981 May; 17(5):502-4. PubMed ID: 7233673
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of aztreonam against other antibiotics used in urinary tract infections.
    Khan MT; Shah SH
    J Ayub Med Coll Abbottabad; 2001; 13(4):22-4. PubMed ID: 11873424
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Management of the urethral syndrome in general practice.
    Pelta DE; Bowring AR
    Practitioner; 1985 Jan; 229(1399):47-9. PubMed ID: 3887354
    [No Abstract]   [Full Text] [Related]  

  • 48. Comparison of enoxacin and norfloxacin in patients with cystitis.
    Yamamoto M; Nagai T; Takaba H; Hashimoto J; Miyake K
    Hinyokika Kiyo; 1987 Dec; 33(12):2141-4. PubMed ID: 3482344
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fleroxacin versus norfloxacin in the treatment of urinary tract infections: a multicenter, double-blind, prospective, randomized, comparative study.
    Pummer K
    Am J Med; 1993 Mar; 94(3A):108S-113S. PubMed ID: 8452165
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Norfloxacin versus nalidixic acid in the treatment of urinary tract infections.
    Karachalios GN; Georgiopoulos AN
    Int J Clin Pharmacol Ther Toxicol; 1987 Jun; 25(6):317-9. PubMed ID: 3623736
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A clinical comparison of cinoxacin and nalidixic acid in the treatment of urinary tract infection.
    Bucy JG
    J Urol; 1981 Jun; 125(6):822-4. PubMed ID: 7017171
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treating acute urinary tract infections. An RCT of 3-day versus 7-day norfloxacin.
    Trienekens TA; London NH; Houben AW; De Jong RA; Stobberingh EE
    Can Fam Physician; 1993 Mar; 39():514-8. PubMed ID: 8471899
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Microbiological and clinical study of spectinomycin in urinary tract infections: reevaluation with hospital strains.
    Schoutens E; Peromet M; Yourassowsky E
    Curr Ther Res Clin Exp; 1972 Jul; 14(7):349-57. PubMed ID: 4261426
    [No Abstract]   [Full Text] [Related]  

  • 54. Single-dose ciprofloxacin versus 3 days of norfloxacin in uncomplicated urinary tract infections in women.
    Auquer F; Cordón F; Gorina E; Caballero JC; Adalid C; Batlle J;
    Clin Microbiol Infect; 2002 Jan; 8(1):50-4. PubMed ID: 11906502
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anti-microbial resistance stratified by risk factor among Escherichia coli strains isolated from the urinary tract at a rural clinic in Central India.
    Chatterjee B; Kulathinal S; Bhargava A; Jain Y; Kataria R
    Indian J Med Microbiol; 2009; 27(4):329-34. PubMed ID: 19736402
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effectiveness and tolerability of aztreonam in urinary tract infection caused by multiresistant bacteria.
    Muzzonigro G; Minardi D; Caraceni E; Villanova A; Polito M
    Acta Urol Belg; 1987; 55(3):485-90. PubMed ID: 3661329
    [No Abstract]   [Full Text] [Related]  

  • 57. Cinoxacin for treatment and prevention of recurrent urinary tract infection.
    Landes RR
    Urology; 1981 May; 17(5):505-10. PubMed ID: 7015670
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Successful use of reduced dosage of cinoxacin in the treatment of recurrent urinary infection.
    Brumfitt W; Smith GW; Hamilton-Miller JM; Bax R
    J Antimicrob Chemother; 1985 Dec; 16(6):781-8. PubMed ID: 4093347
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy.
    Cox CE; Simmons JR
    South Med J; 1982 May; 75(5):549-50. PubMed ID: 7043747
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Occurrence and antibiotic sensitivity of Enterobacteriaceae isolated from a group of Jordanian patients with community acquired urinary tract infections.
    Abu Shaqra Q
    Cytobios; 2000; 101(396):15-21. PubMed ID: 10697742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.